DK2796100T3 - Geldannende system til fjernelse af nyrestenfragmenter - Google Patents
Geldannende system til fjernelse af nyrestenfragmenter Download PDFInfo
- Publication number
- DK2796100T3 DK2796100T3 DK13164955.0T DK13164955T DK2796100T3 DK 2796100 T3 DK2796100 T3 DK 2796100T3 DK 13164955 T DK13164955 T DK 13164955T DK 2796100 T3 DK2796100 T3 DK 2796100T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- gel
- kidney
- fragments
- use according
- Prior art date
Links
- 208000000913 Kidney Calculi Diseases 0.000 title claims description 72
- 206010029148 Nephrolithiasis Diseases 0.000 title claims description 71
- 239000012634 fragment Substances 0.000 title claims description 67
- 239000000203 mixture Substances 0.000 claims description 135
- 239000002245 particle Substances 0.000 claims description 44
- 229920000642 polymer Polymers 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 28
- 238000004132 cross linking Methods 0.000 claims description 26
- 229920001282 polysaccharide Polymers 0.000 claims description 26
- 150000004676 glycans Chemical class 0.000 claims description 25
- 239000005017 polysaccharide Substances 0.000 claims description 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 22
- 229920001661 Chitosan Polymers 0.000 claims description 19
- 210000003734 kidney Anatomy 0.000 claims description 19
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 17
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 16
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 16
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 14
- 239000003431 cross linking reagent Substances 0.000 claims description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 12
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 11
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims description 11
- 229960004502 levodopa Drugs 0.000 claims description 10
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 7
- -1 AINiCo Inorganic materials 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 4
- 238000006062 fragmentation reaction Methods 0.000 claims description 4
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 230000005294 ferromagnetic effect Effects 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims 4
- 229910006297 γ-Fe2O3 Inorganic materials 0.000 claims 1
- 239000000499 gel Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 30
- 230000001070 adhesive effect Effects 0.000 description 21
- 239000000017 hydrogel Substances 0.000 description 19
- 239000000853 adhesive Substances 0.000 description 17
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 235000015110 jellies Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108010029541 Laccase Proteins 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002845 discoloration Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 229920006184 cellulose methylcellulose Polymers 0.000 description 2
- 239000011153 ceramic matrix composite Substances 0.000 description 2
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- BRERHJJSDHDERR-YFKPBYRVSA-N (2r)-2-(tert-butylamino)-3-sulfanylpropanoic acid Chemical compound CC(C)(C)N[C@@H](CS)C(O)=O BRERHJJSDHDERR-YFKPBYRVSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- DQUHYEDEGRNAFO-QMMMGPOBSA-N (2s)-6-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCN DQUHYEDEGRNAFO-QMMMGPOBSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023435 Kidney small Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00876—Material properties magnetic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/26—Materials or treatment for tissue regeneration for kidney reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (10)
1. Geldannende sammensætning, omfattende en sammensætning (A), indeholdende en eller flere kationisk krydsbindende polymerer, og en sammensætning (B), indeholdende et eller flere krydsbindingsmidler til krydsbinding af den eller de kationisk krydsbindende polymerer til anvendelse ved en fremgangsmåde til indlejring og til fjernelse af nyresten og/eller nyrestenfragmenter i/fra et område af en nyre, som indeholder nyresten og/eller nyrestenfragmenter, som skal fjernes, med de følgende trin: (i) tilvejebringelse af sammensætning (A) og (B), (ii) indføring af sammensætning (A) og (B) i et område af nyren, som indeholder nyresten og/eller nyrestenfragmenter, som skal fjernes, under betingelser, som ved kontakt af sammensætning (A) med sammensætning (B) muliggør en krydsbinding af den eller de kationisk krydsbindende polymerer, således at der opstår en krydsbundet gel, som delvist eller fuldstændigt omslutter nyrestenene og/eller nyrestenfragmenterne, der skal fjernes, hvorved det gøres muligt at fjerne de indlejrede nyresten og/eller nyrestenfragmenter, der skal fjernes, (iii) fjernelse af den krydsbundne gel samt de af denne omsluttede nyresten og/eller nyrestenfragmenter fra nyren.
2. Geldannende sammensætning til anvendelse ifølge krav 1, hvor den ene eller de flere eller samtlige kationisk krydsbindende polymer(er) af sammensætning (A) er udvalgt hhv. er fra gruppen bestående af polysaccharider, især polysaccharider med deprotonerede eller deprotonerbare funktionelle grupper, fortrinsvis carboxylgrupper, fortrinsvis polysaccharider fra gruppen af polyuronider, særligt foretrukket polysaccharider fra gruppen af alginater, pektiner og natrium-carboxymethylcellulose (CMC) funktionaliseret med 3,4-dihydroxyphenylalanin (DOPA).
3. Geldannende sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor det ene eller de flere eller samtlige krydsbindingsmidler af sammensætning (B) er udvalgt hhv. er fra gruppen bestående af di- og trivalente kationer, fortrinsvis jern- og kalciumioner.
4. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætning (B) har en sur pH-værdi, fortrinsvis en pH-værdi i området fra 3,5 til 4,5.
5. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor den geldannende sammensætning derudover indeholder magnetiserbare partikler, hvor - de magnetiserbare partikler er en bestanddel af sammensætning (A) og/eller bestanddel af sammensætning (B) og/eller - den geldannende sammensætning derudover omfatter en sammensætning (C), som indeholder magnetiserbare partikler, hvor man ud over sammensætning (A) og (B) derefter også tilvejebringer sammensætning (C) i trin (i) og i trin (ii) og indfører den tidsforskudt eller samtidig med sammensætning (A) eller sammensætning (B), således at den krydsbundne gel derudover indeholder magnetiserbare partikler.
6. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor de magnetiserbare partikler er udvalgt fra partikler indeholdende eller bestående af ferromagnetiske elementer såsom jern, nikkel og kobolt samt legeringer såsom AINiCo, SmCo, Nd2Fei4B, Ni80Fe20, NiFeCo og/eller disses oxider såsom jernoxidpartikler, især jernoxidnanopartikler af Fe304 og/eller y-Fe203.
7. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætning (A) og/eller sammensætning (B) yderligere indeholder chitosan, fortrinsvis, hvor sammensætning (B) indeholder chitosan.
8. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætning (A) og (B) i trin (ii) indføres efter hinanden eller sammen.
9. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor sammensætning (B) indføres før sammensætning (A) i trin (ii).
10. Geldannende sammensætning til anvendelse ifølge et af de foregående krav, hvor fremgangsmåden omfatter det følgende yderligere trin, som tidsmæssigt sker før trin (ii): fragmentering af en eller flere nyresten i nyren, således at der opstår to eller flere, fortrinsvis et stort antal nyrestenfragmenter.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164955.0A EP2796100B1 (de) | 2013-04-23 | 2013-04-23 | Gelbildendes System zum Entfernen von Nierensteinfragmenten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2796100T3 true DK2796100T3 (da) | 2016-08-01 |
Family
ID=48143191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13164955.0T DK2796100T3 (da) | 2013-04-23 | 2013-04-23 | Geldannende system til fjernelse af nyrestenfragmenter |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10232079B2 (da) |
| EP (2) | EP2796100B1 (da) |
| JP (1) | JP2016519957A (da) |
| KR (2) | KR20200040931A (da) |
| CN (1) | CN105491966B (da) |
| AU (1) | AU2013387206B2 (da) |
| CA (1) | CA2910201C (da) |
| DK (1) | DK2796100T3 (da) |
| ES (1) | ES2577102T3 (da) |
| PL (1) | PL2796100T3 (da) |
| WO (1) | WO2014173467A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3875075B1 (de) * | 2020-03-02 | 2023-05-17 | Technische Universität München | Zubereitung zur magnetisierung von nierensteinen und nierensteinfragmenten und kit zur entfernung von nierensteinen und nierensteinfragmenten |
| CN112294842B (zh) * | 2020-11-06 | 2022-12-09 | 合肥大族科瑞达激光设备有限公司 | 一种保护肾脏组织的钬激光碎石保护液 |
| US11903666B2 (en) | 2020-11-20 | 2024-02-20 | The Board Of Trustees Of The Leland Stanford Junior University | Magnetic wire for retrieval and elimination of calculus from the urinary tract |
| KR102580016B1 (ko) * | 2020-12-29 | 2023-09-18 | 부산대학교병원 | 결석을 제거하기 위한 알긴산 겔 복합체 및 이의 제조방법 |
| US11576744B2 (en) * | 2021-03-25 | 2023-02-14 | The Regents Of The University Of California | Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stones |
| EP4101398A1 (de) | 2021-06-09 | 2022-12-14 | Purenum GmbH | Mehr-komponenten-zusammensetzung zur entfernung von partikeln |
| DE202021103106U1 (de) | 2021-06-09 | 2022-06-20 | Purenum Gmbh | Mehr-Komponenten-Zusammensetzung zur Entfernung von Partikeln |
| DE102021123107A1 (de) | 2021-09-07 | 2023-03-09 | Urotech Gmbh | Gelbildendes System zur Verwendung in einem Verfahren zum Entfernen wenigstens eines Fremdkörpers aus einem Trakt eines Patienten |
| CN114522277B (zh) * | 2022-01-11 | 2022-11-18 | 广州医科大学附属第五医院 | 一种原位凝胶的设计合成及其在去除结石与碎片药物中的应用 |
| CN117883148A (zh) * | 2024-01-16 | 2024-04-16 | 辉擎医疗科技(嘉兴)有限公司 | 一种碎石提取系统 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244913A (en) | 1991-11-19 | 1993-09-14 | Baxter International Inc. | Compositions and methods for dissolving body calculi |
| US6642363B1 (en) | 1996-09-19 | 2003-11-04 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
| WO2001000544A1 (fr) | 1999-06-25 | 2001-01-04 | Nippon Kayaku Kabushiki-Kaisha | Composition d'agents gazogenes |
| US6730299B1 (en) | 1999-07-21 | 2004-05-04 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
| IT1317359B1 (it) | 2000-08-31 | 2003-06-16 | Fidia Advanced Biopolymers Srl | Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e |
| US6565530B2 (en) | 2001-02-28 | 2003-05-20 | Scimed Life Systems, Inc. | Immobilizing objects in the body |
| US6906050B2 (en) | 2001-05-31 | 2005-06-14 | Miravant Pharmaceuticals, Inc. | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis |
| WO2004080343A2 (en) | 2003-03-10 | 2004-09-23 | The Regents Of The University Of Michigan | Compositions and methods for use of alginate dural sealants |
| JP4898447B2 (ja) | 2003-10-14 | 2012-03-14 | プルーロームド インコーポレイテッド | 結石破砕術の際の腎結石破片の閉じ込め |
| WO2005110395A1 (en) | 2004-05-19 | 2005-11-24 | University Of South Carolina | System and device for magnetic drug targeting with magnetic drug carrier particles |
| US20060074409A1 (en) * | 2004-10-05 | 2006-04-06 | Scimed Life Systems, Inc. | Detachable shaft medical retrieval device and related methods of use |
| KR20080033159A (ko) | 2005-05-02 | 2008-04-16 | 플루로메드, 인코포레이티드 | 신장 결석의 비석쇄 치료법 |
| US7993302B2 (en) | 2006-05-09 | 2011-08-09 | Stephen Hebert | Clot retrieval device |
| JP2010510814A (ja) | 2006-09-29 | 2010-04-08 | プルーロームド インコーポレイテッド | 砕石術の間の結石および断片の後方移動の防止方法 |
| WO2008105961A2 (en) | 2006-10-10 | 2008-09-04 | Mayo Foundation For Medical Education And Research | Reducing contrast agent-induced toxicity |
| KR20160089544A (ko) | 2007-02-22 | 2016-07-27 | 플루로메드, 인코포레이티드 | 수술후 생물학적 유체 흐름을 제어하기 위한 역 감열 폴리머의 용도 |
| WO2009070766A2 (en) * | 2007-11-27 | 2009-06-04 | Board Of Regents, The University Of Texas System | Functionalization of micro-and nano particles for selective attachment to calcium biomineral surfaces |
| US8734527B2 (en) | 2007-12-20 | 2014-05-27 | Advanced Technologies And Regenerative Medicine, Llc | Encapsulated kidney tissue |
| WO2009088319A1 (ru) * | 2007-12-29 | 2009-07-16 | Physics Depertment M.V. Lomonosov Moscow State University | Магнитные полимерные гранулы и способ формирования блокирующей гелевой пробки |
| EP2082755A1 (de) | 2008-01-16 | 2009-07-29 | CellMed AG | Monolithische in-situ vernetzte Alginatimplantate |
| CN101700422A (zh) | 2009-11-10 | 2010-05-05 | 上海英诺伟医疗器械有限公司 | 一种结构紧凑的体腔封堵器械 |
| US8652366B2 (en) * | 2010-11-01 | 2014-02-18 | Board Of Regents, The University Of Texas System | Aerosol-mediated particle synthesis |
| EP2796101B1 (de) | 2013-04-23 | 2016-04-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Kit zum Herstellen eines vernetzten Gels zum Umschließen von Nierensteinen und/oder Nierensteinfragmenten |
-
2013
- 2013-04-23 DK DK13164955.0T patent/DK2796100T3/da active
- 2013-04-23 ES ES13164955.0T patent/ES2577102T3/es active Active
- 2013-04-23 PL PL13164955T patent/PL2796100T3/pl unknown
- 2013-04-23 EP EP13164955.0A patent/EP2796100B1/de active Active
- 2013-08-22 US US14/786,810 patent/US10232079B2/en active Active
- 2013-08-22 KR KR1020207010523A patent/KR20200040931A/ko not_active Application Discontinuation
- 2013-08-22 WO PCT/EP2013/067434 patent/WO2014173467A1/de active Application Filing
- 2013-08-22 EP EP13756034.8A patent/EP2988681A1/de not_active Withdrawn
- 2013-08-22 CA CA2910201A patent/CA2910201C/en active Active
- 2013-08-22 KR KR1020157033270A patent/KR20160004321A/ko active Search and Examination
- 2013-08-22 AU AU2013387206A patent/AU2013387206B2/en active Active
- 2013-08-22 JP JP2016509309A patent/JP2016519957A/ja active Pending
- 2013-08-22 CN CN201380077477.3A patent/CN105491966B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2910201C (en) | 2020-03-24 |
| KR20200040931A (ko) | 2020-04-20 |
| US10232079B2 (en) | 2019-03-19 |
| EP2796100A1 (de) | 2014-10-29 |
| CA2910201A1 (en) | 2014-10-30 |
| EP2988681A1 (de) | 2016-03-02 |
| WO2014173467A1 (de) | 2014-10-30 |
| JP2016519957A (ja) | 2016-07-11 |
| AU2013387206B2 (en) | 2019-01-24 |
| CN105491966A (zh) | 2016-04-13 |
| CN105491966B (zh) | 2018-06-26 |
| US20160067373A1 (en) | 2016-03-10 |
| PL2796100T3 (pl) | 2016-08-31 |
| EP2796100B1 (de) | 2016-04-20 |
| AU2013387206A1 (en) | 2015-11-12 |
| KR20160004321A (ko) | 2016-01-12 |
| ES2577102T3 (es) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2796100T3 (da) | Geldannende system til fjernelse af nyrestenfragmenter | |
| Ghobril et al. | The chemistry and engineering of polymeric hydrogel adhesives for wound closure: a tutorial | |
| JP7504473B2 (ja) | 多様な湿潤表面用の生体から着想を得た分解性の強靭な接着剤 | |
| US9925311B2 (en) | Kit for producing a crosslinked gel for surrounding urinary calculi and/or fragments thereof | |
| US7029688B2 (en) | Methods and compositions to prevent formation of adhesions in biological tissues | |
| CN105377963B (zh) | 疏水性组织粘着剂 | |
| JP2003192597A (ja) | 癒着防止剤 | |
| EP3177330A1 (en) | Elastic biopolymer and use as a tissue adhesive | |
| Cholewinski et al. | Underwater contact behavior of alginate and catechol-conjugated alginate hydrogel beads | |
| US20160243275A1 (en) | Polymer hydrogel adhesives formed with multiple crosslinking mechanisms at physiologic ph | |
| US20090028957A1 (en) | Implantable Tissue-Reactive Biomaterial Compositions and Systems, and Methods of Us Thereof | |
| Ren et al. | Alginate hydrogel-coated syringe needles for rapid haemostasis of vessel and viscera puncture | |
| Liang et al. | A Janus hydrogel sealant with instant wet adhesion and anti-swelling behavior for gastric perforation repair | |
| Wang et al. | An antibacterial and antiadhesion in situ forming hydrogel with sol–spray system for noncompressible hemostasis | |
| Liu et al. | Peptide/glycyrrhizic acid supramolecular polymer: An emerging medical adhesive for dural sealing and repairing | |
| Chen et al. | Adhesive submucosal injection material based on the nonanal group-modified poly (vinyl alcohol)/α-cyclodextrin inclusion complex for endoscopic submucosal dissection | |
| Unal et al. | Engineering elastic sealants based on gelatin and elastin‐like polypeptides for endovascular anastomosis | |
| Xu et al. | Injectable and Biocompatible Mussel‐Inspired Adhesive for Enhanced Reendothelialization of Injured Artery | |
| WO2015174643A1 (ko) | 표면 처리된 나노섬유를 포함하는 하이드로젤 및 이의 제조방법 | |
| Shao et al. | A Janus hydrogel that enables wet tissue adhesion and resists abdominal adhesions | |
| DE202013012287U1 (de) | Gelbildendes System zum Entfernen von Nierensteinfragmenten | |
| Winkler | Bioinspired Adhesives for Fetal Membrane Presealing | |
| CN116672490A (zh) | 一种组织粘合剂及其制备方法和应用 | |
| Ghobril et al. | Journal Name RSCPublishing |